IrishMc67 retweeted
$NWBO #HIV #DCVax #DendriticCells #Immunotherapy
๐ง๐ต๐ฒ ๐ด๐ผ๐ฎ๐น ๐ถ๐ ๐๐ผ ๐ฒ๐ป๐ฑ ๐๐ฟ๐ฒ๐ฎ๐๐บ๐ฒ๐ป๐ ๐๐ถ๐๐ต๐ผ๐๐ ๐น๐ผ๐๐ถ๐ป๐ด ๐ฐ๐ผ๐ป๐๐ฟ๐ผ๐น ๐ผ๐ณ ๐๐๐ฉ.
HIV medicines suppress the virus. Silent infected cells can remain behind and restart it when treatment stops.
Kalinski and Mailliardโs type 1 dendritic-cell approach, called ฮฑDC1, addresses that hidden infection through the immune systemโs own instructors.
๐๐
๐ฝ๐ผ๐๐ฒ ๐๐ต๐ฒ ๐ถ๐ป๐ณ๐ฒ๐ฐ๐๐ถ๐ผ๐ป. ๐ฃ๐ฟ๐ฒ๐ฝ๐ฎ๐ฟ๐ฒ ๐๐ต๐ฒ ๐ฎ๐๐๐ฎ๐ฐ๐ธ. ๐ ๐ฎ๐ธ๐ฒ ๐ฐ๐ผ๐ป๐๐ฟ๐ผ๐น ๐น๐ฎ๐๐.
In patient-derived laboratory cultures, prepared dendritic cells helped bring latent HIV into view. In separate experiments, dendritic cells presenting HIV fragments generated killer T cells that attacked infected targets and suppressed infectious viral outgrowth.
Those are real biological components of an HIV-cure strategy. Lasting control in people is the clinical goal.
The new JCI Insight paper takes the next question inside the vaccine: which cells supply its strong immune instruction, and how can that function be made more consistent?
The ฮฑDC1 preparation produced substantially more active IL-12 than the PGE2-matured comparator. The small percentage of cells detected making IL-12 is a laboratory measurement of one function, not a patient response rate.
๐ง๐ต๐ฒ ๐ฎ๐ถ๐บ ๐ถ๐ ๐ฑ๐ฒ๐ฝ๐ฒ๐ป๐ฑ๐ฎ๐ฏ๐น๐ฒ ๐ฝ๐ผ๐๐ฒ๐ป๐ฐ๐, ๐ฏ๐ฎ๐๐ฐ๐ต ๐ฎ๐ณ๐๐ฒ๐ฟ ๐ฏ๐ฎ๐๐ฐ๐ต.
That is where Northwestโs Kalinski-related licenses and ฮฑDC1 manufacturing work matter. The company is building the production and clinical-development capabilities needed to turn these cell designs into reproducible medicines.
The full article connects the HIV findings, helper-cell licensing, IL-7 support and Northwestโs manufacturing role around that single purpose: immune control that outlasts treatment.
๐๐๐น๐น ๐ฎ๐ฟ๐๐ถ๐ฐ๐น๐ฒ โ
teapawt.net/andrewcaravello/articlโฆ
$NWBO
Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset
insight.jci.org/articles/vieโฆ
This paper compares two types of DC vaccine: ฮฑDC1 and PGE2-DC (pgDC). Dr. Kalinski is one of the authors.
Hereโs the really interesting part. Both vaccines were also tested head-to-head in a clinical trial โ not in cancer, but in HIV (DC-HIV04, NCT03758625).
So if you think DC vaccines can only treat cancer, think again.
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure (DC-HIV04)
clinicaltrials.gov/study/NCTโฆ
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure
reporter.nih.gov/search/y6Buโฆ
Autologous Dendritic Cell Vaccine in HIV1 Infection
clinicaltrials.gov/study/NCTโฆ
IrishMc67 retweeted
โSoonโ #MHRA will approve #DCVax. Approval will rewrite the oncology playbook, reset safety & efficacy bars while eroding billions in pipeline value across big pharma. Eyes on the horizon. $nwbo
$NWBO
The current situation of NWBO being short raided by market makers trading in dark pools.
Very well described in a Picasso painting and a supporting danish quote.
Nร
R KRYBBEN ER TOM BIDES HESTENE
They want real shares instead of the artificial garbage theyโve made themselves.
Itโs now bagholding becomes a disciplinary act of faith.
$NWBO #DCVax The closest treatment the world has ever known for the cure for cancer and it's trading below $0.14. The manipulation is criminal. People dying and the focus is purely on dollars. Unreal. @DrOzCMS @mcuban @joerogan @billmaher @MHRAgovuk @SecKennedy @realDonaldTrump
IrishMc67 retweeted
Replying to @MAHA_Action
#RareDisease #DIPG #DCVaxForBraelyn #GBM
One in ten children. Ten thousand rare diseases. Five percent have a treatment.
That five percent is the FDA's own number, printed in the notice that opened its Rare Disease Framework docket last month.
๐๐๐ฃ๐ ๐ถ๐ ๐ถ๐ป ๐๐ต๐ฒ ๐ผ๐๐ต๐ฒ๐ฟ ๐ป๐ถ๐ป๐ฒ๐๐ ๐ณ๐ถ๐๐ฒ.
Six years to diagnose? Not here. One MRI. Weeks, not years.
๐ง๐ต๐ฒ๐๐ฒ ๐ฐ๐ต๐ถ๐น๐ฑ๐ฟ๐ฒ๐ป ๐ฎ๐ฟ๐ฒ ๐ฐ๐ฎ๐๐ด๐ต๐ ๐ฒ๐ฎ๐ฟ๐น๐ ๐ฎ๐ป๐ฑ ๐ฑ๐ถ๐ฒ ๐ฎ๐ป๐๐๐ฎ๐.
Most are past five. They die between five and ten instead, usually within a year of the scan. Fewer than one in ten lives two years.
They are not lost to an incapacity to diagnose. They are lost after it.
Steroids for the swelling. Radiation for a few months. Treating symptoms is exactly what they already get, and it is the ceiling.
#๐๐๐ฉ๐ฎ๐
๐ถ๐ ๐๐ต๐ฒ ๐๐ฎ๐บ๐ฒ ๐ฝ๐ฟ๐ถ๐ป๐ฐ๐ถ๐ฝ๐น๐ฒ. The patient's own dendritic cells, loaded with the patient's own tumor. Built for adults with resected glioblastoma. A child's brainstem cannot be resected, so the tissue has to be grown first.
That step works. Tumor from 17 of 18 DIPG biopsies has been grown in culture. At UCLA, one vaccinated child was still being treated thirteen months on, from material already in storage.
๐ง๐ต๐ฒ ๐ฑ๐ผ๐ฐ๐ธ๐ฒ๐ ๐ถ๐ ๐ผ๐ฝ๐ฒ๐ป ๐ฟ๐ถ๐ด๐ต๐ ๐ป๐ผ๐. FDA-2026-N-12214. Comments close December 11.
The proposal is already in it. Add yours.
๐ง๐ฟ๐ฒ๐ฎ๐ ๐๐ต๐ฒ ๐ฐ๐ต๐ถ๐น๐ฑ๐ฟ๐ฒ๐ป.
$NWBO #DCVax #RareCancer
FDAโs Rare Disease Framework is an opportunity for DCVax-L and DCVax-Direct.
๐๐ฟ๐ถ๐ป๐ด ๐ฏ๐ผ๐๐ต ๐ฝ๐ฟ๐ผ๐ด๐ฟ๐ฎ๐บ๐ ๐ณ๐ผ๐ฟ๐๐ฎ๐ฟ๐ฑ.
The complete evidence, practical FDA steps and companion video:
$NWBO #DCVax @DrOzCMS @SecKennedy @Siobhain_Mc @MHRAgovuk
Do the right thing and get this life-saving treatment approved now! GBM patients cannot wait!!
Replying to @jstrattman @Siobhain_Mc
I got the DCVax in 2015 @UCLAStrokeNSG by one of its creators Dr. Linda Liau after the grim diagnosis of a Glioblastoma Multiforme. Iโve thrived for over 11 & a half years. NO TUMOR RECURRENCE!!! How many times do I have to tell my story, it feels like Iโm screaming into an echo chamber. F.F.S it works.
@LisainNJUSA @kshaughnessy2 @DCVaxDefender @HollensbeAmanda @peter_brit @TheLastWord @LastWeekTonight
IrishMc67 retweeted
$NWBO #DCVax #GBM #SFDA
๐ข๐ป๐ฒ ๐ฃ๐ฟ๐ผ๐ฑ๐๐ฐ๐ ๐๐ฒ๐ณ๐ ๐ฆ๐๐ฎ๐ป๐ฑ๐ถ๐ป๐ด
London and Riyadh signed a regulatory agreement this week. It covers rare disease treatments and advanced therapies. It names no product.
It does not need to. Line up the evidence and one product is left.
๐ญ. ๐ง๐ต๐ฒ ๐ฏ๐ฟ๐ถ๐ฑ๐ด๐ฒ
Nov 16 and 17: the heads of the MHRA and the Saudi Food and Drug Authority sign a memorandum of understanding in London. Scope: rare disease treatments, advanced therapies, biotechnology products. Working clauses: product assessment, GMP, product testing, supply chain monitoring. Stated aim: patients with limited therapeutic options.
๐ฎ. ๐ช๐ต๐ผ ๐ป๐ฒ๐ฒ๐ฑ๐ ๐ฎ ๐ฏ๐ฟ๐ถ๐ฑ๐ด๐ฒ
Saudi reliance pathways recognize the FDA and the EMA. Not the MHRA. They exclude advanced therapies outright. A product the FDA or EMA has approved does not need London to vouch for it. An MHRA-only cell therapy does.
๐ฏ. ๐ง๐ต๐ฒ ๐ฒ๐น๐ถ๐บ๐ถ๐ป๐ฎ๐๐ถ๐ผ๐ป
Casgevy: approved in Saudi Arabia since January 2024.
Lyfgenia and Zynteglo: FDA-approved, licensed to SPIMACO. No UK leg.
Multikine: Saudi Breakthrough route plus a US trial. No UK filing announced.
Fayuvi: the FDA approved it before the MHRA took the file.
MeiraGTx's LCA4 gene therapy: MHRA-first by plan, no Saudi partner announced.
mRNA cancer vaccines: one Phase 3 win, in melanoma. Unproven in cold tumors, and the MHRA's own rare disease draft sets them apart.
๐ฐ. ๐ง๐ต๐ฒ ๐๐๐ฟ๐๐ถ๐๐ผ๐ฟ
DCVax-L. A rare cancer. A living cell therapy made one patient at a time. The MHRA its only regulator since December 2023. Phase 3 in JAMA Oncology: 13 percent of newly diagnosed patients alive at five years, against 5.7 percent in external controls.
๐ฑ. ๐ง๐ต๐ฒ ๐ฐ๐น๐ฎ๐๐๐ฒ๐ ๐ณ๐ถ๐
GMP: the Sawston plant has held an MHRA commercial manufacturing license since 2023, one that allows export worldwide.
Supply chain: NHS Blood and Transplant joined cell collection and processing in October.
Assessment: one dossier, one regulator, in London.
๐ฒ. ๐ง๐ต๐ฒ ๐ฆ๐ฎ๐๐ฑ๐ถ ๐๐ถ๐ฑ๐ฒ
Aug 5: the Saudi FDA issues a rare disease accelerator. It takes products through Phase 3 that are not yet registered in the Kingdom. It accepts natural history data as an external comparator when a concurrent control is not feasible. The UK is on its list of countries whose GMP certificates and inspection reports it accepts.
Aug 6: Northwest Bio and SPIMACO announce an MOU that would give SPIMACO the Saudi FDA filing.
SPIMACO has a dedicated unit for biological, gene and cell therapies.
Saudi Breakthrough status is open only to products not yet registered with any regulator. A request has to go in before London rules, not after.
At the London summit, the Saudi FDA chief called for faster access to innovative treatments "tailored to their needs," naming rare disease patients and specialized therapies.
๐ณ. ๐ง๐ต๐ฒ ๐จ๐ ๐๐ถ๐ฑ๐ฒ
2014: DCVax-L receives the UK's first-ever Promising Innovative Medicine designation.
Nov 2025: the MHRA's rare therapies paper says large randomized trials in small populations can be "unfeasible and potentially unethical."
Feb 2026: England's National Cancer Plan gives rare cancers their own chapter and names brain tumours a priority.
March 2026: the Rare Cancers Act orders a review of orphan drug rules for cancer.
Oct 2026: after the Prime Minister meets a brain cancer patient, the government tells the MHRA to speed up its orphan drug review.
๐ด. ๐ง๐ต๐ฒ ๐ฝ๐ฟ๐ฒ๐ฐ๐ฒ๐ฑ๐ฒ๐ป๐
Casgevy. The MHRA approved it first, on Nov 16, 2023. Saudi approval was announced 54 days later.
๐ต. ๐ง๐ต๐ฒ ๐๐ฒ๐ฒ๐ธ
Same week in London: the MHRA hosts the ICMRA conference on drug development for small patient populations, and the five Access Consortium regulators agree on a secure platform for work-sharing.
The MHRA has not ruled yet. But the plant is licensed, the Saudi filer is named, the Saudi door is open, and the two regulators now have a direct line.
Remove every product that does not need this agreement. One is left.
#dcvax $nwbo #gbm
MHRA - A significant step forward for international Regulatory Collaboration..
linkedin.com/posts/medicinesโฆ
investorshub.advfn.com/boardโฆ
Replying to @DrOzCMS
@DrOzCMS @SecKennedy @Siobhain_Mc @MHRAgovuk
Please listen to and follow Dr. Caravello!! You will learn what youโre seeking. Heโll show you the answers you seek for brain cancer (all solid tumors actually)! #DCVax is the way and heโll explain how!
Replying to @Siobhain_Mc
$NWBO #DCVax #DCVaxForBraelyn #Glioblastoma
Siobhain, please put Braelyn Hollensbe and DCVax-L at the centre of this debate. Sharon Hodgson raised Braelynโs case in the Commons on 4 November.
๐ฃ๐ต๐ฎ๐๐ฒ ๐๐๐ ๐ถ๐ ๐ฐ๐ผ๐บ๐ฝ๐น๐ฒ๐๐ฒ. ๐ง๐ต๐ฒ ๐ฟ๐ฒ๐๐๐น๐๐ ๐ฎ๐ฟ๐ฒ ๐ฝ๐๐ฏ๐น๐ถ๐๐ต๐ฒ๐ฑ.
DCVax-L has completed a 331-patient phase III trial. Its published survival analysis reported five-year survival of 13.0% versus 5.7% in external controls.
Subsequent patient-level propensity-score matching, presented at BNOS, reported median survival advantages of 3.4โ6.3 months. A separate weighting method produced directionally consistent findings.
INSIGhT independently tested the external-control approach against known randomized results. Carefully matched external controls reproduced the absence of survival benefit for three experimental drugs. That gives the method a concrete benchmark in glioblastoma.
๐ก๐๐ฆ ๐๐น๐ผ๐ผ๐ฑ ๐ฎ๐ป๐ฑ ๐ง๐ฟ๐ฎ๐ป๐๐ฝ๐น๐ฎ๐ป๐ ๐ถ๐ ๐ฎ๐น๐ฟ๐ฒ๐ฎ๐ฑ๐ ๐๐๐ฝ๐ฝ๐ผ๐ฟ๐๐ถ๐ป๐ด ๐ฝ๐ฟ๐ผ๐ฑ๐๐ฐ๐๐ถ๐ผ๐ป.
On 8 October, NHS Blood and Transplant announced a collaboration with Northwest Biotherapeutics and Advent BioServices to support DCVax-L production, initially involving Leeds and Oxford.
This is a patient-derived treatment: the patientโs own dendritic cells are loaded with material from that patientโs tumor. The phase III publication described treatment as well tolerated.
CheckMate 143, 498 and 548 failed to improve survival in glioblastoma. Ipi-Glio failed too. WIN-Glio is a separate phase I study testing ipilimumab before standard treatment. Its recruitment, safety and survival reporting should be transparent.
๐๐ผ๐บ๐ฏ๐ถ๐ป๐ฎ๐๐ถ๐ผ๐ป ๐ฑ๐ฒ๐๐ฒ๐น๐ผ๐ฝ๐บ๐ฒ๐ป๐ ๐บ๐๐๐ ๐ฎ๐ฑ๐ฑ๐ฟ๐ฒ๐๐ ๐ถ๐บ๐บ๐๐ป๐ฒ ๐ถ๐ป๐๐๐ฟ๐๐ฐ๐๐ถ๐ผ๐ป.
Put DCVax-L at the foundation of that work: prepare the cells that teach the immune response, then test the partners that sustain its attack. Dendritic-cell vaccination and checkpoint blockade address complementary parts of the task.
The UK marketing application was submitted in December 2023. Northwestโs November 2026 filing still describes the MHRA review as ongoing.
What specific issues remain unresolved? Who is responsible for resolving them, and on what timetable? What patient-access arrangements are being prepared alongside the review?
๐ฃ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐ฐ๐ฎ๐ป๐ป๐ผ๐ ๐๐ฝ๐ฒ๐ป๐ฑ ๐๐ต๐ฒ ๐ฟ๐ฒ๐๐ ๐ผ๐ณ ๐๐ต๐ฒ๐ถ๐ฟ ๐น๐ถ๐๐ฒ๐ ๐๐ฎ๐ถ๐๐ถ๐ป๐ด ๐ณ๐ผ๐ฟ ๐ฎ๐ป๐๐๐ฒ๐ฟ๐.
EVIDENCE
DCVax-L phase III results and safety:
jamanetwork.com/journals/jamโฆ
BNOS propensity-score matching and weighting analyses:
nwbio.com/wp-content/uploadsโฆ
INSIGhT external-control reanalysis:
pubmed.ncbi.nlm.nih.gov/4217โฆ
NHSBT production collaboration:
nwbio.com/northwest-biotheraโฆ
Current company filing on the MHRA review:
sec.gov/Archives/edgar/data/โฆ
CheckMate 143:
pmc.ncbi.nlm.nih.gov/articleโฆ
CheckMate 498:
pmc.ncbi.nlm.nih.gov/articleโฆ
CheckMate 548:
pmc.ncbi.nlm.nih.gov/articleโฆ
Ipi-Glio:
pubmed.ncbi.nlm.nih.gov/4080โฆ
WIN-Glio registration:
clinicaltrials.gov/study/NCTโฆ
UCLA combination research using its academic ATL-DC vaccine, Hiltonol and pembrolizumab:
clinicaltrials.gov/study/NCTโฆ
Braelynโs case raised in Parliament:
hansard.parliament.uk/pdf/coโฆ
@Siobhain_Mc Amanda @HollensbeAmanda listened to him and now look at how well Braelyn @HollensbeBrae is thriving!!
3
29
IrishMc67 retweeted
#NWBO's DCVax-L has been saving lives for 20 years and still no approval?!?!?!?!
WTF!!!!
$NWBO
@NorthwestBioโs DCVax platform saved Brad Silverโs life.
More than 20 years ago he was diagnosed with glioblastoma and given 2 months to live.
Then he met Dr Linda Liau and Dr. Robert M. Prins at @UCLAStrokeNSG and was accepted into a clinical trial for DCVax.
DCVax is a non-toxic promising Phase 3 treatment for glioblastoma and all solid tumors.
Thanks @peter_brit for the find.
IrishMc67 retweeted
Replying to @JG_Nuke
Michael Intrator $CRWV CEO dumps ~ $1B in stock yet Wall Street and Silicon Valley calls them "visionaries" or "pioneers."
Meanwhile โa biotech CEO like $NWBO Linda Powers holds hundreds of millions of locked-up shares, lends her own cash to the company at 0% interest, yet @adamfeuerstein villainizes her after actually saving cancer patients.
โWatch what insiders DO with their own money not what some talking head crank says on social media or CNBC.
Standard of Care does NOT do this for GBM patients today! This life-saving treatment needs to be approved NOW!! Patients canโt wait!! @DrOzCMS @FDADrugs @MHRAgovuk @SecKennedy
$NWBO #DCVax
โค๏ธ๐ ANOTHER MRI. ANOTHER ANSWERED PRAYER!
NO EVIDENCE OF DISEASE!!! ๐โค๏ธ
Today, Braelyn had another brain MRI, and I am absolutely OVERJOYED to share that it once again showed NO EVIDENCE OF DISEASE!
NO CHANGE from her August MRI!
And just FOUR DAYS AGO, on Friday, November 6, Braelyn received her 5th DCVax-L treatment in London! ๐ฌ๐ง
I cannot begin to describe the emotions.
After more than three years of fighting this devastating brain cancer, three major brain tumor surgeries, radiation, countless treatments, and more fear than I ever imagined a mother could endure, we are now celebrating another MRI showing NO EVIDENCE OF DISEASE!
I wish I could tell you that the scanxiety gets easier. But it doesnโt. At least not for me.
Every MRI brings back the memories of devastating scans, heartbreaking news, and the terrifying uncertainty of what might come next.
I still find myself holding my breath, praying desperately for those words.
And today, we heard them again.
NO EVIDENCE OF DISEASE. โค๏ธ๐
My heart is overflowing with gratitude.
To every single person who has prayed for Braelyn, supported our family, donated to help make her treatments possible, shared her story, or simply sent us words of encouragementโTHANK YOU!
You have helped carry us through the darkest days of our lives, and you are now helping us celebrate some of the brightest.
And to Northwest Biotherapeutics ($NWBO), the brilliant Dr. Linda Liau at UCLA, and the extraordinary Professor Keyoumars Ashkan at Kingโs College Hospitalโthere are simply no words adequate to express our gratitude.
Thank you for your dedication, your compassion, and your determination to bring new hope to patients facing this devastating disease.
Braelyn is 19 years old. Sheโs attending college. Sheโs dreaming about her future.
And today, once again, her MRI shows NO EVIDENCE OF DISEASE!
GOD IS GOOD! โค๏ธ๐
#DCVax #BrainCancer #BraelynsFight #NoEvidenceOfDisease
#DCvaxForBraelyn
IrishMc67 retweeted
$NWBO @LessIsM14781097
uclahealth.org/news/article/โฆ
DUD, did you see what Linda Liau had to say about DCVax-L that validates everything Iโve said about ATL-DC the last 4 years and make your โemail correspondenceโ a make believe happening in Never Neverland?
โThe vaccine, an autologous tumor lysate-pulsed dendritic cell vaccination (ATL-DC) known as DCVax-Lโ
Ouch.
Adam Feuerstein lied, you lied, exwannabe lied and Jerry Campbell stickied the lie.
Thatโs how LieHub rolls!
This is from me. The new crypto currency, Judas Coin.
A commemorative token to remember all the bullshit you lot brought to the game during the last 4 years.
Replying to @FlemmingBruce
Dud, did you see that Dr. Prins had nothing to say about NWBO, validates (again) the e-mail exchange we had many years ago.
Past performance can be indicative of future results.
Independent research and analysis could possibly prevent the financial situation you're in (again).
IrishMc67 retweeted
The 19.3 vs 16.5 median is the least interesting number in the dataset. Focusing only on that and calling it a press release ignores what was published in JAMA Oncology.
5-year survival was 13.0% with DCVax-L vs 5.7% in matched external controls. Recurrent disease was 13.2 vs 7.8 months (HR 0.58). These are peer-reviewed Phase 3 results, not a company release.
Individual patient-level propensity score matching against external controls from multiple trials later showed larger advantages than the original 2.8-month median difference on the order of 3.4 to 6.3 months depending on the comparator.
And no, this is not built on โone mechanic from Kent.โ
Jeannine Walston (first patient on the DCVax platform at UCLA, diagnosed 1998) is now approaching three decades. Other long-term GBM survivors associated with Liauโs work include:
โขJennifer, 25+ years
โขBrad, 22+ years
โขElijah, 18+ years
โขGallia, 14+ years
โขJamil, 13+ years
IrishMc67 retweeted
โค๏ธ THIS is why we keep fighting!
Andrew, I cannot thank you enough for the extraordinary time, research, and dedication youโve poured into this proposal.
You understand something that families like ours know all too well: Accessing a promising treatment is only half the battle. Being able to CONTINUE that treatment is just as important.
Braelyn is 19, attending college, and her latest MRI shows NO EVIDENCE OF DISEASE. Yet we must continue traveling across the Atlantic and raising tens of thousands of dollars for each DCVax treatment.
No family fighting for their childโs life should have to face these barriers.
To see Braelynโs story helping inspire meaningful proposals to the FDAโand being shared in the British Parliament in the SAME WEEKโis almost surreal!
My deepest hope is that the doors weโre fighting to open for Braelyn will remain open for every patient who comes after her.
Thank you, Andrew, for standing with us and turning compassion into action. โค๏ธ๐๐บ๐ธ๐ฌ๐ง
Please read Andrewโs proposal and add your voice to the FDAโs public comment process!
$NWBO #DCVax #DCVaxForBraelyn #RareCancer #RareDisease #Immunotherapy #PatientAdvocacy #GBM
๐งฌ ๐ง๐ต๐ฒ ๐๐๐ฉ๐ฎ๐
๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐๐ฎ๐น ๐ถ๐ ๐ป๐ผ๐ ๐ผ๐ป ๐๐ต๐ฒ ๐๐๐ ๐ฟ๐ฒ๐ฐ๐ผ๐ฟ๐ฑ.
A 19-year-old was in college when she began DCVax-L in London. Treatment had started. Her family was still raising money for the next dose.
Her mother's account stayed with me. Underneath it is one question:
๐๐ผ๐ ๐ฑ๐ผ๐ฒ๐ ๐ฎ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐ ๐๐๐ฎ๐ฟ๐ ๐๐ฟ๐ฒ๐ฎ๐๐บ๐ฒ๐ป๐ ๐ฎ๐ป๐ฑ ๐ธ๐ฒ๐ฒ๐ฝ ๐ด๐ฒ๐๐๐ถ๐ป๐ด ๐ถ๐?
On November 6, my 21-page proposal became part of the public record for the FDA's Rare Disease Framework Initiative. I filed it as a physician and patient advocate, independent of Northwest Biotherapeutics.
Both treatments start with the patient's own dendritic cells, the cells that teach T cells what to recognize. DCVax-L introduces them to material from the patient's tumor in the lab. DCVax-Direct is injected into a lesion so they meet the tumor there. Same cells, two ways to show them the target.
Rare cancers come with no playbook for getting a treatment like this and keeping it. The proposal asks FDA to write one, using ๐๐๐ฉ๐ฎ๐
-๐ ๐ฎ๐ป๐ฑ ๐๐๐ฉ๐ฎ๐
-๐๐ถ๐ฟ๐ฒ๐ฐ๐ as the working example.
๐ง๐ต๐ฒ ๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐๐ฎ๐น ๐ฎ๐๐ธ๐ ๐๐๐ ๐ณ๐ผ๐ฟ ๐๐ต๐ฟ๐ฒ๐ฒ ๐๐ต๐ถ๐ป๐ด๐, ๐ถ๐ป ๐๐ฟ๐ถ๐๐ถ๐ป๐ด:
1. What the evidence supports for each treatment.
2. Who must arrange to preserve tumor tissue before surgery.
3. Who is responsible for supply and follow-up, so a family knows whom to call when the next dose is due.
Plain answers, on paper, so the next family is not guessing.
๐ ๐ฅ๐ฒ๐ฎ๐ฑ ๐๐ต๐ฒ ๐ฝ๐๐ฏ๐น๐ถ๐ฐ ๐ณ๐ถ๐น๐ถ๐ป๐ด
regulations.gov/comment/FDA-โฆ
๐ ๐ข๐ฝ๐ฒ๐ป ๐๐ต๐ฒ ๐ณ๐๐น๐น ๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐๐ฎ๐น ยท ๐ฎ๐ญ ๐ฝ๐ฎ๐ด๐ฒ๐ ยท ๐ฑ๐ฎ ๐๐ผ๐๐ฟ๐ฐ๐ฒ๐
mirrulations.s3.amazonaws.coโฆ
๐ช๐ต๐ฎ๐ ๐ฑ๐ผ ๐๐ผ๐ ๐๐ถ๐๐ต ๐๐ผ๐บ๐ฒ๐ผ๐ป๐ฒ ๐ต๐ฎ๐ฑ ๐๐ผ๐น๐ฑ ๐๐ผ๐๐ฟ ๐ณ๐ฎ๐บ๐ถ๐น๐ ๐๐ผ๐ผ๐ป๐ฒ๐ฟ?
FDA is taking public comments through ๐๐ฒ๐ฐ๐ฒ๐บ๐ฏ๐ฒ๐ฟ ๐ญ๐ญ, ๐ฎ๐ฌ๐ฎ๐ฒ. You do not need to be a doctor or a lawyer. A few sentences in your own words count: the barrier your family hit, what it cost the person you love, and the one thing you want FDA to change. To stand behind this proposal, cite ๐๐๐-๐ฎ๐ฌ๐ฎ๐ฒ-๐ก-๐ญ๐ฎ๐ฎ๐ญ๐ฐ-๐ฌ๐ฌ๐ฏ๐ต.
No family should be raising money for the next dose while their child is mid-treatment. ๐ง๐ฒ๐น๐น ๐๐๐.
โ๏ธ ๐๐ฑ๐ฑ ๐๐ผ๐๐ฟ ๐๐ผ๐ถ๐ฐ๐ฒ ๐๐ผ ๐๐ต๐ฒ ๐๐๐ ๐ฑ๐ผ๐ฐ๐ธ๐ฒ๐
regulations.gov/commenton/FDโฆ
๐ฅ ๐ง๐ต๐ฎ๐ ๐ญ๐ต-๐๐ฒ๐ฎ๐ฟ-๐ผ๐น๐ฑ ๐ต๐ฎ๐ ๐ฎ ๐ป๐ฎ๐บ๐ฒ. On Wednesday, Braelyn Hollensbe sat in the gallery of the House of Commons while an MP asked the Government to help get this treatment into widespread use, and the First Secretary of State replied that the Prime Minister has taken a personal interest. One Parliament has asked the question out loud. The FDA docket is where the rest of us ask it.
@FDA @ReaganUdall @RareDiseases @NBTStweets @HollensbeAmanda @mfhugo1 @ThomasOwenMcCa1 @peter_brit @greta @DrOzCMS @DrOz @MelDMann @AlMusella @MHRAgovuk
IrishMc67 retweeted
$NWBO #DCVax #DCVaxForBraelyn #RareCancer #RareDisease #Immunotherapy #PatientAdvocacy #GBM
๐งฌ ๐ง๐ต๐ฒ ๐๐๐ฉ๐ฎ๐
๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐๐ฎ๐น ๐ถ๐ ๐ป๐ผ๐ ๐ผ๐ป ๐๐ต๐ฒ ๐๐๐ ๐ฟ๐ฒ๐ฐ๐ผ๐ฟ๐ฑ.
A 19-year-old was in college when she began DCVax-L in London. Treatment had started. Her family was still raising money for the next dose.
Her mother's account stayed with me. Underneath it is one question:
๐๐ผ๐ ๐ฑ๐ผ๐ฒ๐ ๐ฎ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐ ๐๐๐ฎ๐ฟ๐ ๐๐ฟ๐ฒ๐ฎ๐๐บ๐ฒ๐ป๐ ๐ฎ๐ป๐ฑ ๐ธ๐ฒ๐ฒ๐ฝ ๐ด๐ฒ๐๐๐ถ๐ป๐ด ๐ถ๐?
On November 6, my 21-page proposal became part of the public record for the FDA's Rare Disease Framework Initiative. I filed it as a physician and patient advocate, independent of Northwest Biotherapeutics.
Both treatments start with the patient's own dendritic cells, the cells that teach T cells what to recognize. DCVax-L introduces them to material from the patient's tumor in the lab. DCVax-Direct is injected into a lesion so they meet the tumor there. Same cells, two ways to show them the target.
Rare cancers come with no playbook for getting a treatment like this and keeping it. The proposal asks FDA to write one, using ๐๐๐ฉ๐ฎ๐
-๐ ๐ฎ๐ป๐ฑ ๐๐๐ฉ๐ฎ๐
-๐๐ถ๐ฟ๐ฒ๐ฐ๐ as the working example.
๐ง๐ต๐ฒ ๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐๐ฎ๐น ๐ฎ๐๐ธ๐ ๐๐๐ ๐ณ๐ผ๐ฟ ๐๐ต๐ฟ๐ฒ๐ฒ ๐๐ต๐ถ๐ป๐ด๐, ๐ถ๐ป ๐๐ฟ๐ถ๐๐ถ๐ป๐ด:
1. What the evidence supports for each treatment.
2. Who must arrange to preserve tumor tissue before surgery.
3. Who is responsible for supply and follow-up, so a family knows whom to call when the next dose is due.
Plain answers, on paper, so the next family is not guessing.
๐ ๐ฅ๐ฒ๐ฎ๐ฑ ๐๐ต๐ฒ ๐ฝ๐๐ฏ๐น๐ถ๐ฐ ๐ณ๐ถ๐น๐ถ๐ป๐ด
regulations.gov/comment/FDA-โฆ
๐ ๐ข๐ฝ๐ฒ๐ป ๐๐ต๐ฒ ๐ณ๐๐น๐น ๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐๐ฎ๐น ยท ๐ฎ๐ญ ๐ฝ๐ฎ๐ด๐ฒ๐ ยท ๐ฑ๐ฎ ๐๐ผ๐๐ฟ๐ฐ๐ฒ๐
mirrulations.s3.amazonaws.coโฆ
๐ช๐ต๐ฎ๐ ๐ฑ๐ผ ๐๐ผ๐ ๐๐ถ๐๐ต ๐๐ผ๐บ๐ฒ๐ผ๐ป๐ฒ ๐ต๐ฎ๐ฑ ๐๐ผ๐น๐ฑ ๐๐ผ๐๐ฟ ๐ณ๐ฎ๐บ๐ถ๐น๐ ๐๐ผ๐ผ๐ป๐ฒ๐ฟ?
FDA is taking public comments through ๐๐ฒ๐ฐ๐ฒ๐บ๐ฏ๐ฒ๐ฟ ๐ญ๐ญ, ๐ฎ๐ฌ๐ฎ๐ฒ. You do not need to be a doctor or a lawyer. A few sentences in your own words count: the barrier your family hit, what it cost the person you love, and the one thing you want FDA to change. To stand behind this proposal, cite ๐๐๐-๐ฎ๐ฌ๐ฎ๐ฒ-๐ก-๐ญ๐ฎ๐ฎ๐ญ๐ฐ-๐ฌ๐ฌ๐ฏ๐ต.
No family should be raising money for the next dose while their child is mid-treatment. ๐ง๐ฒ๐น๐น ๐๐๐.
โ๏ธ ๐๐ฑ๐ฑ ๐๐ผ๐๐ฟ ๐๐ผ๐ถ๐ฐ๐ฒ ๐๐ผ ๐๐ต๐ฒ ๐๐๐ ๐ฑ๐ผ๐ฐ๐ธ๐ฒ๐
regulations.gov/commenton/FDโฆ
๐ฅ ๐ง๐ต๐ฎ๐ ๐ญ๐ต-๐๐ฒ๐ฎ๐ฟ-๐ผ๐น๐ฑ ๐ต๐ฎ๐ ๐ฎ ๐ป๐ฎ๐บ๐ฒ. On Wednesday, Braelyn Hollensbe sat in the gallery of the House of Commons while an MP asked the Government to help get this treatment into widespread use, and the First Secretary of State replied that the Prime Minister has taken a personal interest. One Parliament has asked the question out loud. The FDA docket is where the rest of us ask it.
@FDA @ReaganUdall @RareDiseases @NBTStweets @HollensbeAmanda @mfhugo1 @ThomasOwenMcCa1 @peter_brit @greta @DrOzCMS @DrOz @MelDMann @AlMusella @MHRAgovuk
Replying to @ablidy
What an absolute honor to have been invited to sit in the Speakerโs VIP box. A huge Thank You to Sharon Hodgson, Labour MP for highlighting this very important issue affecting so many people in both of our countries, and beyond. We are grateful for the warm reception and the support of our โcousinsโ on the other side of the pond!
#DcVaxForBraelyn
@DrOzCMS
IrishMc67 retweeted
#Glioblastoma $NWBO #DCVax #Immunotherapy #SITC2026 #SITC26
Mel lived the first one. In 1998 a Phase 1 trial took a terminal leukemia and turned it into a disease people grow old with. #Gleevec works because CML runs on one broken switch, BCR-ABL, and one pill can jam it.
The common solid tumors never offered one switch. Each carries its own private set of mutations, and when a drug does find a target the tumor rewires around it. That is why there has never been a Gleevec for the cancers that kill most people.
DCVax-L does not chase mutations. The patient's own dendritic cells are loaded with the whole tumor, not a chosen piece of it, and the immune system picks the targets. In newly diagnosed glioblastoma that produced 13% alive at five years (or more) against 5.7% for propensity score matched external controls. A curve with a tail is what immune memory looks like.
It happened in the textbook cold tumor. Few T cells ever reach a glioblastoma, which is why checkpoint drugs failed there in three Phase 3 trials. A checkpoint drug releases the brakes on T cells that already exist. In a cold tumor there is nothing to release. Dendritic cells sit one step upstream. They create those T cells, so the vaccine does not need the tumor to be warm. It is how a tumor gets warm.
And once it is warm, the checkpoint drug that failed alone finally has something to work with. Dr. Liau's UCLA group tested the order in recurrent glioblastoma and reported the result at EANO 2026. In 35 patients, Keytruda before the vaccine meant a median survival of 271 days. Keytruda after the vaccine meant 555 days, and the risk of death fell by two thirds. Tumor and blood showed why: more T cells in the tumor and more interferon and granzyme when the vaccine came first. Same two drugs, same disease. The order alone doubled survival.
The trial proved the platform in glioblastoma. The platform never cared which tumor the lysate came from, and the sequence does not care either. ๐ง๐ต๐ฎ๐ ๐ถ๐ ๐๐ต๐ฒ ๐๐ฟ๐๐ฒ ๐๐น๐ฒ๐ฒ๐๐ฒ๐ฐ ๐บ๐ผ๐บ๐ฒ๐ป๐, ๐ฎ๐ป๐ฑ ๐๐ต๐ถ๐ ๐๐ถ๐บ๐ฒ ๐ถ๐ ๐ถ๐ ๐ณ๐ผ๐ฟ ๐ฒ๐๐ฒ๐ฟ๐ ๐๐ผ๐น๐ถ๐ฑ ๐๐๐บ๐ผ๐ฟ.
#DCVaxForBraelyn
@HollensbeAmanda
@ThomasOwenMcCa1
@mfhugo1
@MHRAgovuk
@FDA
@DrOzCMS
@greta
@kshaughnessy2
@peterjkostis
@Siobhain_Mc
@parkerici
Glioblastoma rarely gives good news.
The peer-reviewed phase 3 DCVax-L trial showed a statistically significant overall survival benefit in both newly diagnosed and recurrent disease. Brain Tumour Research called the results astonishing.
Any validated survival gain matters for patients and families facing this cancer.
IrishMc67 retweeted
#SITC26 #SITC2026 $NWBO #DCVaxForBraelyn #CancerVaccines #RareCancers
๐๐ก๐ ๐๐๐ซ๐ ๐๐ญ ๐๐ฌ ๐๐ง๐ฅ๐ฒ ๐ญ๐ก๐ ๐๐ญ๐๐ซ๐ญ
What an ovarian-cancer vaccine trial reveals about immune escape, and why #DCVax makes the presenter part of the treatment.
A cancer vaccine can begin with a precise picture of a tumor. Durable control requires the immune response to remain effective as the tumor changes what it produces, displays and needs to survive.
The NeoVax trial reported by Sellars and colleagues investigated an aggressive ovarian-cancer category called high-grade epithelial ovarian cancer. It tested a therapeutic vaccine, meaning a treatment for people already diagnosed with cancer. Nine vaccinated patients were at their first recurrence and one was newly diagnosed, following platinum-based chemotherapy.ยน
Researchers selected abnormal protein sequences from each patient's tumor and manufactured matching fragments, called peptides. NeoVax combined them with the immune stimulant poly-ICLC. Nivolumab, which releases an immune brake, began later. Ten patients received vaccine; blood markers of tumor burden showed patterns consistent with activity in six.ยน
That is meaningful activity. It also leaves the question that matters most to the patient: can the response keep controlling the cancer as the cancer changes?
Dendritic cells occupy a crucial position in that question. They take up material, process it and display fragments to T cells, immune cells that coordinate or carry out an attack. Their accompanying signals help determine what kind of response develops. The antigen supplies something to recognize; the presenting cell helps establish what the receiving cells will do about it.ยฒ
๐๐ก๐๐ซ๐ ๐๐ซ๐ ๐ญ๐ฐ๐จ ๐๐ข๐ฌ๐ฉ๐ฅ๐๐ฒ๐ฌ ๐ข๐ง ๐ญ๐ก๐ข๐ฌ ๐ฌ๐ญ๐จ๐ซ๐ฒ. The dendritic cell displays a fragment to teach a T cell. The cancer cell must display a compatible target for that trained killer T cell to recognize it. A successful first encounter does not guarantee a successful second one.
The ovarian trial exposed several escape routes. Some tumors had lost genes encoding HLA, the molecules that display targets on cell surfaces. Recurrence samples lost selected vaccine-target mutations. In another patient, an alteration in JAK1 impaired the tumor's response to interferon, an immune signal that can increase antigen display. Restoring JAK1 in laboratory-grown tumor models restored recognition by vaccine-specific T cells.ยน
That is a failure of access to the target. An immune cell can be capable of recognizing a particular display while the cancer no longer makes that display. Personalizing a target to the patient's genetic background does not ensure that the surviving tumor remains visible through it.
Nivolumab blocks an inhibitory receptor on T cells. Blocking that receptor does not replace a missing tumor gene or restore a lost target. Releasing a brake and making the cancer recognizable are different biological jobs.ยณ
Vivek Subbiah and colleagues' new review examines cancer plasticity, the ability of cancer cells to change their identity and behavior. Some transformed lung cancers retain the mutation that originally guided treatment while changing their protein expression and losing sensitivity to drugs aimed at that pathway. The DNA finding remains real while the tumor's biology has moved on. The review also describes changes in antigen display and the immune surroundings during transformation. For vaccination, the implication is temporal: recognition must remain matched to the cancer that exists now.โด
This is where the DCVax approach changes the design of the intervention. The treatment includes the patient's prepared dendritic cells, bringing antigen presentation itself into the product.
DCVax-L brings those cells together with material from the patient's removed tumor outside the body. The material is processed into tumor lysate, a mixture of cellular contents that provides an antigen source for the dendritic cells.โต
DCVax-Direct takes a different route. Cells collected from the patient's blood are developed and partially activated outside the body, then injected into an accessible tumor. They are intended to acquire tumor material there and help initiate an immune response.โถ
๐๐๐ง๐๐ซ๐ข๐ญ๐ข๐ ๐๐๐ฅ๐ฅ๐ฌ ๐๐จ ๐๐ข๐จ๐ข๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐๐ฌ ๐๐จ๐ซ ๐ ๐ฅ๐ข๐ฏ๐ข๐ง๐ . They process complex tumor material into fragments that can be displayed through the patient's own presentation molecules. Their condition also shapes the signals delivered with those fragments. NeoVax calls on this machinery inside the patient. DCVax makes prepared dendritic cells part of the medicine, allowing the presenter's condition to be shaped and examined before administration.
This is the biological substance behind calling dendritic cells instructors. Their work extends beyond holding up a target. A helper T cell can recognize their display and return a licensing signal, strengthening their ability to support cancer-killing T cells. The helper and killer need not arrive simultaneously; the conditioned dendritic cell can connect their encounters across time.โท
IL-12 adds another instruction, supporting the coordinated cellular attack called type 1 immunity. Activated T cells can return interferon gamma, prompting dendritic cells to produce IL-12. Tumor experiments have demonstrated the importance of this reciprocal exchange during PD-1 blockade. The response depends on cells supporting one another, not merely on the presence of a recognizable antigen.โธ
Preparation can change the outcome of that conversation. In human-cell experiments, researchers presented the same cancer-associated fragment using differently conditioned dendritic cells. Helper-conditioned cells generated stronger measured killing responses and T cells with features associated with immune memory. ๐๐ก๐ ๐ญ๐๐ซ๐ ๐๐ญ ๐ฌ๐ญ๐๐ฒ๐๐ ๐ญ๐ก๐ ๐ฌ๐๐ฆ๐. ๐๐ก๐ ๐ข๐ง๐ฌ๐ญ๐ซ๐ฎ๐๐ญ๐ข๐จ๐ง ๐๐ก๐๐ง๐ ๐๐.โน
The material is collected at a moment; the immune response must operate over time. DCVax-L's lysate comes from a particular collection. Direct's repeated injections offer encounters with material present in a lesion at later times.โถ
The host response can also broaden beyond its starting targets through epitope spreading, the development of responses to additional antigens. A human melanoma trial combining a different type 1 dendritic-cell vaccine with dasatinib documented responses beyond its vaccine peptides. A starting sample need not be the final boundary of recognition.ยนโฐ
DCVax-Direct's phase I trial also examined activity at the tumor site. ๐๐ข๐ญ๐ก๐จ๐ฎ๐ญ ๐๐๐ฒ๐ญ๐ซ๐ฎ๐๐, biopsies showed increased immune-cell infiltration in about 54% of assessed patients across several advanced cancers. The study identified helper and killer T cells and local immune activity. It also found increased PD-L1, an inhibitory signal, in 19 of 25 evaluated tumors.โถ
Those observations give checkpoint combinations a specific rationale: address a brake appearing alongside a response. They also make clear that the activity observed with Direct was already present without a checkpoint drug.
This continuing response still needs a reachable target. A manufactured dendritic cell does not reconstruct HLA genes deleted from a cancer cell. If one recognition route is lost, control requires an effective remaining route or another way to attack. Broad antigen acquisition, useful instruction and tumor vulnerability have to remain connected.
๐๐ข๐ญ๐ก๐จ๐ฎ๐ญ ๐๐ง ๐๐๐๐๐๐ญ๐ข๐ฏ๐ ๐ฐ๐๐ฒ ๐ญ๐จ ๐๐จ๐ง๐ญ๐ซ๐จ๐ฅ ๐ญ๐ก๐ ๐ฌ๐ฎ๐ซ๐ฏ๐ข๐ฏ๐ข๐ง๐ ๐๐๐ง๐๐๐ซ, ๐ข๐ฆ๐ฆ๐ฎ๐ง๐ ๐๐๐ญ๐ข๐ฏ๐๐ญ๐ข๐จ๐ง ๐๐๐ง๐ง๐จ๐ญ ๐ฉ๐ซ๐จ๐๐ฎ๐๐ ๐ ๐๐ฎ๐ซ๐๐๐ฅ๐ ๐ซ๐๐ฌ๐ฉ๐จ๐ง๐ฌ๐. Treatment must preserve the cancer's vulnerability, restore it, or overcome its escape through another effective mechanism.
๐๐๐ซ๐ฌ๐จ๐ง๐๐ฅ๐ข๐ณ๐๐ญ๐ข๐จ๐ง ๐ฆ๐ฎ๐ฌ๐ญ ๐ซ๐๐ฆ๐๐ข๐ง ๐๐ฎ๐ซ๐ซ๐๐ง๐ญ. A precise description of yesterday's cancer is a starting point. Durability requires an immune response that can keep controlling the cancer that survives today.
๐๐จ๐ฎ๐ซ๐๐๐ฌ
1. Sellars and colleagues, Nature Medicine (2026). Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial. Author manuscript and main/extended-data figures reviewed.
nature.com/articles/s41591-0โฆ
2. Nobel Prize scientific background: dendritic cells and adaptive immunity.
nobelprize.org/prizes/mediciโฆ
3. National Cancer Institute: nivolumab and PD-1 blockade.
cancer.gov/publications/dictโฆ
4. Kuburich, Gouda and colleagues; Mani and Subbiah. Cancer plasticity and histological transformation as adaptive resistance mechanisms in precision oncology. Med (online October 13, 2026). Supplied 23-page corrected proof read in full, including all five figures and the reference list. The connections to DCVax are this essay's synthesis.
doi.org/10.1016/j.medj.2026.โฆ
5. Liau and colleagues, Journal of Translational Medicine (2018). Cited for DCVax-L preparation using autologous tumor lysate and dendritic cells.
pmc.ncbi.nlm.nih.gov/articleโฆ
6. Subbiah and colleagues, Clinical Cancer Research (2018). DCVax-Direct preparation and phase I findings without Keytruda. Published maturation used GM-CSF, killed BCG and interferon gamma, with no added PGE2 listed.
pmc.ncbi.nlm.nih.gov/articleโฆ
7. Ridge and colleagues, Nature (1998). Dendritic-cell conditioning as a temporal bridge between helper and killer T cells.
pubmed.ncbi.nlm.nih.gov/9624โฆ
8. Garris and colleagues, Immunity (2018). Reciprocal IFN-gamma and IL-12 signaling during anti-PD-1 treatment in tumor models.
pubmed.ncbi.nlm.nih.gov/3055โฆ
9. Simon and colleagues, Biological Research (2012). Human dendritic-cell conditioning, cytotoxic responses and memory-associated phenotypes in culture.
pubmed.ncbi.nlm.nih.gov/2268โฆ
10. Storkus and colleagues. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. JITC (2021). Cited for human epitope spreading in a distinct DC-vaccine/dasatinib regimen.
pubmed.ncbi.nlm.nih.gov/3478โฆ
A phase 1 clinical trial of a personalized NeoVax vaccine showed that treatment was safe and well tolerated, with early evidence of immune and clinical efficacy bit.ly/4imhd5h
๐ In a phase 1 clinical trial, Sellars et al. evaluated the adjuvant use of personalized cancer vaccines in combination with nivolumab in patients with high-grade ovarian cancer treated with standard-of-care platinum-based chemotherapy. Treatment was feasible and well tolerated, with evidence of vaccine-induced T cell responses and antitumor immunity. Immune escape through several mechanisms was also observed.
@danaFarber
@harvardmed
IrishMc67 retweeted
Replying to @DrOz
@DrOz @RobertKennedyJr @POTUS $NWBO
Would be great to see Amanda and Braelyn in the Oval Office next week with President Trump, Dr Oz, RFK Jr, Dr Liau, Dr. Bosch, Dr Boyton, and Linda Powers to bring forward a pathway for Americans to get DCVAX-L and expedite the approval, especially since it appears MHRA and NHS are on the verge of approving with the UK PM stepping in today. We then need to work on getting the basket trials for all solid tumors and DCVAX-L approved and moving forward. The world could use some good news now and a Cancer break-through 20+ years in the making would greatly help MANKIND!
Congratulations on your visit to the UK Parliament today Amanda and Braelyn while on your trip to get Braelyns 5th injection of DCVAX.
Hoping this is your last visit to the UK for a treatment! Take care Amanda and Braelyn and safe travels!
Do Better @FDA Americans depend on you!
What an absolute honor to have been invited to sit in the Speakerโs VIP box. A huge Thank You to Sharon Hodgson, Labour MP for highlighting this very important issue affecting so many people in both of our countries, and beyond. We are grateful for the warm reception and the support of our โcousinsโ on the other side of the pond!
#DcVaxForBraelyn
@DrOzCMS
IrishMc67 retweeted
Replying to @parkerici
$NWBO
#SITC26 #DCVax #DCVaxForBraelyn #CancerVaccines #RareCancers #Glioblastoma
@parkerici @sitcancer @DanaFarber @SharonHodgsonMP @MHRAgovuk @HollensbeAmanda
๐ฃ๐ต๐ผ๐ฒ๐ป๐ถ๐
๐๐ ๐๐ถ๐๐ฐ๐๐๐๐ถ๐ป๐ด ๐๐. ๐ฃ๐ฎ๐ฟ๐น๐ถ๐ฎ๐บ๐ฒ๐ป๐ ๐๐๐๐ ๐๐๐ธ๐ฒ๐ฑ ๐๐ผ๐ฟ ๐๐.
Thirty-two sessions on cancer vaccines open in Phoenix today. Congratulations to Catherine J. Wu on the Smalley Award. The field has never been more convinced that the immune system can be taught.
This morning, an ocean away, the House of Commons was looking at a patient it already worked for.
Braelyn Hollensbe was given three months to live at 16. She is 19, she was in the gallery at Prime Minister's Questions, and her scans show no evidence of disease.
Sharon Hodgson MP put the whole problem in three facts. The drug is manufactured in the UK. It is the first treatment in decades shown to extend survival in recurrent glioblastoma. It reaches only a tiny number of patients, by exception.
The First Secretary of State welcomed Braelyn and said the Health Secretary will look at this urgently.
Here is the distinction the Phoenix program will spend five days circling.
A sequencer can list a tumour's mutations. It cannot teach them. Antigen selection and antigen instruction are different contributions, and in a patient whose cancer and treatment have already depleted the immune system, the missing piece is the instructor.
๐๐ฒ๐ป๐ฑ๐ฟ๐ถ๐๐ถ๐ฐ ๐ฐ๐ฒ๐น๐น๐ ๐ฑ๐ผ ๐ฏ๐ถ๐ผ๐ถ๐ป๐ณ๐ผ๐ฟ๐บ๐ฎ๐๐ถ๐ฐ๐ ๐ณ๐ผ๐ฟ ๐ฎ ๐น๐ถ๐๐ถ๐ป๐ด.
Nobody picked Braelyn's targets. Her own cells read the whole tumour and chose.
The marketing application for that vaccine has been with the MHRA for 1,050 days.
The science is on stage in Phoenix this week. The patient was in Parliament this morning. The file has been on a regulator's desk since December 2023.
Approve it.
#DCVaxForBraelyn



























